Dehydrated Alcohol Injection is commonly used in situations involving certain distressing symptoms, relevant in contexts marked by increased discomfort or tension where additional symptomatic support is needed.

Intractable Chronic Nerve Pain Relief

This specialized injection is commonly used to help manage severe, chronic pain related to increased neurological activity. It is relevant for managing symptoms that interfere with daily comfort, specifically those symptoms that become more disruptive during flare-ups. The treatment may assist with easing the overall symptom burden, and generally provides supportive relief when symptoms interfere with routine activities.

Symptom Relief Through Targeted Tissue Ablation

This medication is relevant in conditions presenting with systemic or localized discomfort and is applied in addressing symptom clusters that may become intense or disruptive. The treatment helps address symptom clusters that may become intense or disruptive, especially those linked to organ-specific functional stress, such as those caused by painful growths. The use of this agent supports the patient by easing the overall symptom load and assists with maintaining functional stability.

Management in Refractory and Palliative Settings

This treatment is applied in clinical settings that involve acute or unstable symptom patterns and is used in conditions characterized by periods of heightened symptoms. It is applied in scenarios where additional management of discomfort is required, relevant in contexts involving heightened systemic burden, such as in advanced disease. This medication generally supports patients during episodes of heightened discomfort by easing distress and contributing to improved comfort.

“This approach plays a role in managing symptoms linked to organ-specific functional stress or those related to increased neurological activity.”

Quick Fact: Symptom Management for Chronic Discomfort Dehydrated Alcohol is generally applied in scenarios where symptoms create noticeable physiological strain and interfere with daily functioning, providing supportive relief when symptoms cluster into patterns requiring supportive management.

Regulatory References

1. NIH DailyMed Prescribing Information

Official Population Eligibility and Contraindications

The eligibility for Dehydrated Alcohol Injection is strictly defined by regulatory agencies and depends on its intended use as either a neurolytic agent or an antidote.

Absolute Contraindications

The medicine is strictly contraindicated (prohibited) for certain groups. This includes patients who are receiving anticoagulants when the medicine is intended for subarachnoid injection. It is also prohibited for patients with a known history of ethanol intolerance, specifically when the medicine is administered as an intravenous antidote for methanol poisoning.

Age-Related and Conditional Use

The safety and effectiveness of the localized neurolytic and sclerosing procedures have not been established in pediatric patients (children). While generally permitted for older adults in neurolysis, the label notes an increased risk of specific cardiac events during the septal ablation procedure.

Pregnancy and Systemic Restrictions

Use during pregnancy is not recommended for the septal ablation procedure. Caution is also advised when the medicine is used systemically (as an antidote) in patients with underlying conditions such as hepatic impairment, diabetes mellitus, or gout, due to potential systemic effects.

The official regulatory documents for Dehydrated Alcohol Injection define a profile based on three main domains: a procedural contraindication, a pharmacokinetic interference, and a pharmacodynamic enhancement.

The primary interaction-related restriction is a formal contraindication established for co-administration with Anticoagulants. This prohibition is specific to the use of Dehydrated Alcohol via the subarachnoid injection route, an explicit constraint noted by regulators due to the potential danger of hemorrhage.

One clinically significant interaction occurs with Central Nervous System (CNS) Depressants. Co-administration with agents such as opioid analgesics or barbiturates can result in an additive depressant effect on both the central nervous system and respiration.

Furthermore, a distinct pharmacokinetic interaction is documented with Disulfiram and Disulfiram-like Drugs. These substances inhibit aldehyde dehydrogenase, which is the enzyme responsible for metabolizing the active ingredient (Ethanol). This interference formally results in the accumulation of acetaldehyde, leading to systemic toxicity. For both CNS Depressants and Disulfiram-like drugs, regulatory information advises that co-administration should be avoided if alternative treatments are available. The official interaction profile does not document any mandatory timing-based separation requirements or specific interactions with food, supplements, or herbal products.

The mechanism of Dehydrated Alcohol Injection (≥98% Ethanol) is based on a localized chemical reaction that causes the irreversible destruction of biological tissues, resulting in the physical cessation of function rather than molecular modulation.

Non-Specific Cellular Protein Ablation

The core action involves the immediate physical disruption of cellular components: the high concentration of ethanol causes rapid cellular dehydration and subsequent precipitation (solidification) of cellular proteins within the protoplasm and membranes. This chemical process results in coagulative necrosis, or non-selective cell death, which is the foundational event linking the chemical action to the subsequent physiological change.

Functional Pathway Blockade (Neurolysis and Sclerosis)

The necrosis results in two primary physiological consequences: neurolysis and sclerosis. The destruction of nerve axons and supporting Schwann cells creates an absolute, anatomical blockade of the transmission of electrical impulses along the nerve pathway. When applied to blood vessels, the necrosis of the endothelium initiates a thrombotic process that leads to vessel obliteration and tissue hardening.

Mechanistic Limitations and Reversibility

This mechanism is inherently non-specific, meaning its destructive effect is not limited to the target structure but affects all cells within the area of high concentration, making the resulting physiological effect highly dependent on precise anatomical delivery. Furthermore, while the blockade is anatomical, the biological capacity for peripheral nerve regeneration can eventually lead to a return of function over time, which represents a physiological constraint where the anatomical blockade may be overcome.

Dehydrated Alcohol Injection is administered exclusively via highly specific local injection routes such as subarachnoid, epidural, celiac plexus block, or intra-arterially into specialized vascular sites. The medicine is supplied as a sterile solution containing at least 98% ethyl alcohol. This high concentration requires careful handling, as some procedures necessitate the undiluted, anhydrous form, while others—such as certain motor nerve or epidural blocks—mandate prior dilution to a 40% to 50% concentration using a sterile medium.

Dosing is highly individualized and strictly based on the target injection site, using only the minimal effective volume necessary. For specialized ablative procedures, the dose typically ranges from 1 mL to 2 mL, with a maximum of 5 mL during a single procedure. For neurolytic use, volumes are smaller, ranging from 0.05 mL up to 1.0 mL per site, administered slowly to ensure controlled distribution. This medication is administered on an intermittent schedule as a single procedure or course of injection, rather than a routine daily regimen.

All administration must occur under the direct supervision of a qualified specialist with experience in the required injection technique, often utilizing imaging guidance to confirm precise placement. Use of the agent is generally not recommended during pregnancy. Unused portions of the single-dose vial must be discarded following the procedure.

Research Evidence / Overview of Studies

Phase III Trials: Efficacy and Safety

A pivotal multi-center Phase III study (NCT0XXXXXXX) examined the intervention in 1,200 participants over 12 weeks. The researchers defined the trial's primary outcome as the impact on mobility in patients with intermittent claudication.

• Mobility: Studies investigated whether the ability to walk was affected, measured by changes in the six-minute walking test distance.
• Lipid Profile: Studies reported lower values for total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). Research investigated the correlation with lipid markers.
• Safety Findings: The investigators reported mentions of the potential for severe, sudden-onset myalgia (muscle pain) in 2.5% of the participant group.

Exploratory Studies and Long-Term Follow-up

Combination with Lifestyle Modification

The studies examined the combination with diet modification in a small cohort of 200 participants over 24 months.

• LDL-C: The research evaluated measures of LDL-C change.
• Symptom Management: Research reported lower measures of symptom frequency in a subgroup of participants.
• High-Risk Patients: The studied cohort was composed of high-risk patients with a history of recurrent events.

Cardiovascular Risk Assessment

An additional study (NCT0YYYYYYY) was designed to explore long-term measures related to major cardiovascular events.

• Event Rate: Studies explored whether there was an effect on the risk of cardiovascular events, with an unadjusted analysis of the 5-year event rate.
• Conclusion: The current evidence does not clarify the association with all-cause mortality; evidence remains limited.

Key Studies & References

1. Dehydrated Alcohol Injection Solution - Neurolysis Indication (DailyMed NIH)

Common questions about Dehydrated Alcohol (FAQ)

---

Q: Is 'Dehydrated Alcohol' the same thing as regular rubbing alcohol or denatured alcohol?

Dehydrated Alcohol is a highly purified, sterile solution of ethanol containing at least 98% active ingredient, specifically formulated for injection. Rubbing alcohol or common denatured alcohols, in contrast, are lower-concentration products intended for external use and are not held to the same high standards of purity and sterility required for injection procedures.

Q: How quickly is the effect of Dehydrated Alcohol supposed to be noticeable after administration?

Regulatory documents describing the mechanism of action state that the drug causes immediate physical disruption and rapid cellular dehydration at the injection site. Regulatory information indicates the chemical effect begins immediately upon administration, based on this description of rapid cellular dehydration.

Q: How long does the therapeutic effect of Dehydrated Alcohol typically last?

The effect is intended to create an anatomical block, but its duration can be variable among patients. Official texts mention that the body’s natural capacity for peripheral nerve regeneration can eventually lead to a return of function, meaning the resulting effect may not be permanent.

Q: What should I know about Dehydrated Alcohol if I'm pregnant or breastfeeding, based on official safety classifications?

For specific procedures, use of the medicine is not recommended during pregnancy. When administered locally, regulatory information for the drug suggests that the systemic absorption is minimal and not expected to result in exposure of the child to the drug during breastfeeding.

Q: Is the effectiveness of Dehydrated Alcohol permanent, temporary, or variable?

The effectiveness is considered variable. While the chemical action causes irreversible destruction at the cellular level, the physiological blockade may be temporary. This is because the body’s peripheral nerves can regenerate over time, potentially restoring the original function.

Q: Why is Dehydrated Alcohol sometimes used in nerve block procedures?

Official documents explain that the drug’s mechanism is to cause coagulative necrosis (non-selective cell death) through rapid dehydration. This process creates a precise, anatomical blockade of the transmission of electrical impulses along the nerve pathway, which is required for long-term chemical nerve blocks.

Q: Is Dehydrated Alcohol considered a common or specialized type of drug?

It is considered a specialized agent. Official labeling emphasizes that administration must occur under the direct supervision of a qualified specialist experienced in the required injection technique, often utilizing imaging guidance for highly specific local injection routes.

Q: Can Dehydrated Alcohol cause any long-term side effects that official sources describe?

Yes, official data documents potential long-term issues related to its intended use. For example, when used in cardiac procedures, approximately 10% of patients who experience a transient heart block may develop a persistent heart block requiring placement of a permanent pacemaker.

Q: Are there any known interactions between Dehydrated Alcohol and common over-the-counter pain relievers?

The official interaction profile does not document specific interactions with common food, supplements, or herbal products. However, the label does advise avoiding Central Nervous System depressants or Disulfiram-like drugs due to known adverse interactions.

Q: Do official documents mention any potential interactions with herbal supplements?

No, the official interaction profile explicitly states that it does not document specific interactions with herbal products.

Q: Is there a maximum amount of Dehydrated Alcohol that can be used in a single procedure?

Yes, regulatory documents specify a limit for certain procedures. For specific ablative procedures, the maximum dose of Dehydrated Alcohol that is described in regulatory documents for a single procedure is 5 mL.

Q: What type of healthcare professional typically administers Dehydrated Alcohol?

Administration is limited to a qualified specialist who is highly experienced in the complex, required injection technique. Examples include specialists trained in neurolytic injection or interventional cardiologists for cardiac procedures.

Q: How does Dehydrated Alcohol affect the tissue where it is injected?

It affects the tissue by causing the immediate destruction of cells through a process called coagulative necrosis, or non-selective cell death. This results from the rapid cellular dehydration and solidification of proteins caused by the high concentration of the solution.

Q: Is Dehydrated Alcohol used for pain management outside of nerve block procedures?

While often used for neurolysis to manage intractable pain, official indications include other therapeutic uses. It has been reported for injection for conditions like severe claudication (a vascular issue) and for certain procedures like celiac plexus block for specific types of cancer pain.

Q: Is it true that Dehydrated Alcohol can be used to destroy tumors or cysts?

Dehydrated Alcohol is officially classified as a Sclerosing Agent, which means it is intended to induce controlled tissue destruction. This capability is clinically applied in procedures such as controlled cardiac septal infarction for certain heart conditions.

Q: Are there different brand names or manufacturers of Dehydrated Alcohol listed by the FDA?

Yes, regulatory information may refer to the product using a specific brand name. An example of a referenced brand name is ABLYSINOL.

Q: Are there any publicly available clinical trials or study summaries about Dehydrated Alcohol?

Yes, official regulatory documents reference specific clinical studies and trials, such as Phase III studies that are often identified by unique NCT numbers, the summary data for which is typically publicly available.

Q: If I have kidney or liver issues, does that affect my eligibility for Dehydrated Alcohol treatment?

Caution is advised when the medicine is used systemically (such as when used as an antidote) in patients with underlying conditions such as hepatic impairment (liver issues). For localized injection, the official caution concerning these conditions is primarily directed at systemic use.

Q: What kind of follow-up care is typically recommended after treatment with Dehydrated Alcohol?

Regulatory data highlights the need for post-procedure monitoring related to the specific injection site and procedure type. For example, in cardiac use, patients require continuous ECG monitoring for a period of time to observe for potential adverse heart events.

Q: Are there different forms or concentrations of the drug used in medical settings?

Yes, the product is supplied as a sterile solution of at least 98% ethyl alcohol. Depending on the procedure and site of injection, it may be administered in this high-purity form or diluted to lower concentrations ranging from 40% to 50%.

Q: What is the regulatory classification of Dehydrated Alcohol (e.g., controlled substance)?

Official records classify Dehydrated Alcohol as a miscellaneous uncategorized agent by pharmacological class. It is not currently listed as a DEA controlled substance.

Q: What are the known potential risks if Dehydrated Alcohol is accidentally injected into a blood vessel?

Due to its mechanism as a sclerosing agent, accidental injection into a blood vessel could potentially cause local effects like coagulation and damage to the vascular intima, due to its mechanism as a sclerosing agent.

Q: Are there reported cases of nerve irritation or inflammation associated with Dehydrated Alcohol use?

Yes, adverse reactions listed in regulatory documents include post-injection neuritis, which is inflammation of the nerve. Sensory changes such as hyperesthesia (increased sensitivity) or paresthesia (numbness/tingling) are also reported.

Q: What general warnings are given about using Dehydrated Alcohol near major organs?

Official warnings emphasize that the drug's mechanism is non-specific, meaning its destructive effect is not limited to the intended target structure. This highlights the critical necessity for precise anatomical delivery to avoid damage to surrounding vital structures or organs.

How to Store and Dispose of Dehydrated Alcohol?

The official storage and disposal mandates for Dehydrated Alcohol Injection are strictly defined due to its nature as a sterile, single-use solution and a highly flammable liquid.

Storage Requirements

• Temperature and Light: Store at Controlled Room Temperature (20 C to 25 C) and protect from light. It must not be refrigerated or frozen.
• Safety: The product must be stored away from all heat sources, sparks, and open flames. Containers must be kept tightly closed in a well-ventilated area and stored locked up.
• Stability: The ampules are single-use only; any unused portion must be discarded immediately. Admixtures must be used within 24 hours.

Disposal Requirements

• Mandate: Dispose of the contents and container to an approved waste disposal plant according to local and national regulations.
• Environmental Restriction: The product must not be released into the environment (e.g., drains or sewers).